Vanda Pharmaceuticals Statistics
Share Statistics
Vanda Pharmaceuticals has 58.31M shares outstanding. The number of shares has increased by 1.32% in one year.
| Shares Outstanding | 58.31M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.16% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 55.22M |
| Failed to Deliver (FTD) Shares | 787 |
| FTD / Avg. Volume | 0.12% |
Short Selling Information
The latest short interest is 3.74M, so 6.41% of the outstanding shares have been sold short.
| Short Interest | 3.74M |
| Short % of Shares Out | 6.41% |
| Short % of Float | 6.77% |
| Short Ratio (days to cover) | 6.21 |
Valuation Ratios
The PE ratio is 96.51 and the forward PE ratio is 27.35. Vanda Pharmaceuticals 's PEG ratio is 0.04.
| PE Ratio | 96.51 |
| Forward PE | 27.35 |
| PS Ratio | 1.26 |
| Forward PS | 1 |
| PB Ratio | 0.44 |
| P/FCF Ratio | 19.5 |
| PEG Ratio | 0.04 |
Enterprise Valuation
Vanda Pharmaceuticals Inc. has an Enterprise Value (EV) of 115.73M.
| EV / Earnings | 46.13 |
| EV / Sales | 0.6 |
| EV / EBITDA | -10.58 |
| EV / EBIT | -8.29 |
| EV / FCF | 9.32 |
Financial Position
The company has a current ratio of 4.94, with a Debt / Equity ratio of 0.
| Current Ratio | 4.94 |
| Quick Ratio | 4.92 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0% and return on capital (ROIC) is -1%.
| Return on Equity (ROE) | 0% |
| Return on Assets (ROA) | 0% |
| Return on Capital (ROIC) | -1% |
| Revenue Per Employee | 948.97K |
| Profits Per Employee | 12.36K |
| Employee Count | 203 |
| Asset Turnover | 0.3 |
| Inventory Turnover | 10.9 |
Taxes
| Income Tax | 3.83M |
| Effective Tax Rate | 0.6 |
Stock Price Statistics
The stock price has increased by 18.3% in the last 52 weeks. The beta is 0.77, so Vanda Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.77 |
| 52-Week Price Change | 18.3% |
| 50-Day Moving Average | 4.83 |
| 200-Day Moving Average | 5.01 |
| Relative Strength Index (RSI) | 39.39 |
| Average Volume (20 Days) | 680.90K |
Income Statement
In the last 12 months, Vanda Pharmaceuticals had revenue of $192.64M and earned $2.51M in profits. Earnings per share was $0.04.
| Revenue | 192.64M |
| Gross Profit | 177.84M |
| Operating Income | -13.95M |
| Net Income | 2.51M |
| EBITDA | -10.94M |
| EBIT | -13.95M |
| Earnings Per Share (EPS) | 0.04 |
Balance Sheet
The company has $135.82M in cash and $9.40M in debt, giving a net cash position of $126.42M.
| Cash & Cash Equivalents | 135.82M |
| Total Debt | 9.40M |
| Net Cash | 126.42M |
| Retained Earnings | -155.39M |
| Total Assets | 645.12M |
| Working Capital | 343.30M |
Cash Flow
In the last 12 months, operating cash flow was $12.80M and capital expenditures -$383.00K, giving a free cash flow of $12.42M.
| Operating Cash Flow | 12.80M |
| Capital Expenditures | -383.00K |
| Free Cash Flow | 12.42M |
| FCF Per Share | 0.22 |
Margins
Gross margin is 92.32%, with operating and profit margins of -7.24% and 1.3%.
| Gross Margin | 92.32% |
| Operating Margin | -7.24% |
| Pretax Margin | 3.29% |
| Profit Margin | 1.3% |
| EBITDA Margin | -5.68% |
| EBIT Margin | -7.24% |
| FCF Margin | 6.45% |
Dividends & Yields
VNDA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 0.87% |
| FCF Yield | 4.64% |
Analyst Forecast
The average price target for VNDA is $15.5, which is 237.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $15.5 |
| Price Target Difference | 237.7% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Scores
| Altman Z-Score | 1.96 |
| Piotroski F-Score | 1 |